论文部分内容阅读
1例65岁男性患者因肺癌术后2年多复发给予厄洛替尼片150 mg,1次/d口服治疗。既往无心血管病史,治疗前心电图正常。治疗第5天患者出现胸闷、头晕,气促症状及短暂晕厥。停药并对症治疗后症状逐渐缓解,心率恢复正常;之后,患者再次服用厄洛替尼再次出现晕厥,心率波动于45～54次/min之间(最低32次/min),频发房性早搏和室性早搏、心房扑动、心房纤颤、窦性停搏及快慢综合征,遂患者接受永久心脏起搏器植入术。
A 65-year-old male patient was given oral administration of erlotinib 150 mg once daily for 2 years after lung cancer recurrence. No past history of cardiovascular disease, ECG before treatment is normal. On the 5th day of treatment, the patient developed chest tightness, dizziness, shortness of breath and short-term syncope. After withdrawal and symptomatic treatment symptoms gradually eased, heart rate returned to normal; then, the patient once again took erlotinib again syncope, heart rate fluctuations between 45 to 54 beats / min (minimum 32 beats / min), frequent room Premature beats and premature ventricular contractions, atrial flutter, atrial fibrillation, sinus arrest and fasting syndrome, then patients undergoing permanent pacemaker implantation.